Poehling Capital Management LLC raised its holdings in shares of CVS Health Corp (NYSE:CVS) by 27.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,446 shares of the pharmacy operator’s stock after purchasing an additional 7,380 shares during the quarter. CVS Health accounts for approximately 1.9% of Poehling Capital Management LLC’s investment portfolio, making the stock its 12th largest holding. Poehling Capital Management LLC’s holdings in CVS Health were worth $2,712,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of CVS Health in the second quarter valued at about $191,000. Exchange Capital Management Inc. grew its position in shares of CVS Health by 6.6% in the second quarter. Exchange Capital Management Inc. now owns 60,276 shares of the pharmacy operator’s stock valued at $3,879,000 after purchasing an additional 3,723 shares during the last quarter. Paragon Capital Management LLC grew its position in shares of CVS Health by 1.3% in the second quarter. Paragon Capital Management LLC now owns 121,576 shares of the pharmacy operator’s stock valued at $7,823,000 after purchasing an additional 1,592 shares during the last quarter. Trillium Asset Management LLC grew its position in shares of CVS Health by 4.5% in the second quarter. Trillium Asset Management LLC now owns 162,359 shares of the pharmacy operator’s stock valued at $10,448,000 after purchasing an additional 6,968 shares during the last quarter. Finally, Arjuna Capital acquired a new stake in shares of CVS Health in the second quarter valued at about $566,000. Institutional investors and hedge funds own 84.50% of the company’s stock.
CVS has been the topic of several research analyst reports. Bank of America raised their price target on CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, September 17th. ValuEngine downgraded CVS Health from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 4th. Tigress Financial reaffirmed a “buy” rating on shares of CVS Health in a research report on Friday, October 26th. Royal Bank of Canada raised their price target on CVS Health to $101.00 and gave the company an “outperform” rating in a research report on Tuesday, September 18th. Finally, Wolfe Research initiated coverage on CVS Health in a research report on Thursday, October 25th. They issued a “peer perform” rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $90.69.
CVS stock opened at $74.09 on Friday. CVS Health Corp has a twelve month low of $60.14 and a twelve month high of $83.88. The stock has a market cap of $78.01 billion, a P/E ratio of 11.23, a PEG ratio of 1.10 and a beta of 0.98. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.94 and a current ratio of 2.44.
CVS Health (NYSE:CVS) last released its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share for the quarter, topping analysts’ consensus estimates of $1.71 by $0.02. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The business had revenue of $47.27 billion for the quarter, compared to the consensus estimate of $47.22 billion. During the same period last year, the business earned $1.50 earnings per share. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. On average, sell-side analysts predict that CVS Health Corp will post 7.03 earnings per share for the current fiscal year.
In other CVS Health news, EVP Lisa Bisaccia sold 21,534 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $80.00, for a total transaction of $1,722,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO David M. Denton sold 25,159 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $80.13, for a total transaction of $2,015,990.67. Following the transaction, the chief financial officer now owns 403 shares of the company’s stock, valued at approximately $32,292.39. The disclosure for this sale can be found here. Over the last three months, insiders have sold 74,233 shares of company stock worth $5,932,565. 0.53% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “CVS Health Corp (CVS) Shares Bought by Poehling Capital Management LLC” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/12/08/cvs-health-corp-cvs-shares-bought-by-poehling-capital-management-llc.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.